Inotek Pharmaceuticals

Inotek Pharmaceuticals is developing molecules with novel mechanisms of action to fulfill major unmet medical needs in significant diseases of the eye. Complete loss of vision or vision impairment currently affects 3.3 million people over the age of 40 in the United States, with the most common diseases including age-related macular degeneration (AMD), glaucoma, cataract and diabetic retinopathy. With the continued aging of the population, the National Eye Institute projects that this number will grow to 5.5 million people by the year 2020.

Type
Public
HQ
Lexington, US
Founded
1996
Size (employees)
17 (est)-5%
Inotek Pharmaceuticals was founded in 1996 and is headquartered in Lexington, US

Key People at Inotek Pharmaceuticals

Paul G. Howes

Paul G. Howes

President and CEO

Inotek Pharmaceuticals Office Locations

Inotek Pharmaceuticals has an office in Lexington
Lexington, US (HQ)
33 Hayden Avenue

Inotek Pharmaceuticals Metrics

Inotek Pharmaceuticals Financial Metrics

Net income (2016)

($42.9 m)

Market capitalization (28-Apr-2017)

$54 m

Closing share price (28-Apr-2017)

$2.1

Cash (31-Dec-2016)

$29.8 m
Inotek Pharmaceuticals's current market capitalization is $54 m.
FY, 2015FY, 2016

R&D expense

($12.6 m)($32 m)

General and administrative expense

($7.8 m)($9.9 m)

Operating expense total

($20.4 m)($41.9 m)

EBIT

($20.4 m)($41.9 m)

Interest expense

($1.2 m)($1.4 m)

Interest income

$89 k$443 k

Net Income

($68 m)($42.9 m)
FY, 2015FY, 2016

Cash

$80 m$29.8 m

Current Assets

$112.4 m$128.3 m

PP&E

$812 k$1.1 m

Total Assets

$113.3 m$129.6 m

Current Liabilities

$4.1 m$7.2 m

Additional Paid-in Capital

$304.6 m$311.8 m

Retained Earnings

($196 m)($238.9 m)

Total Equity

$108.8 m$73.2 m

Financial Leverage

1 x1.8 x
FY, 2015FY, 2016

Net Income

($68 m)($42.9 m)

Depreciation and Amortization

$45 k$169 k

Accounts Receivable

$3 m

Inventories

($263 k)

Accounts Payable

$839 k

Cash From Operating Activities

($17.4 m)($37.3 m)

Purchases of PP&E

($412 k)($487 k)

Cash From Investing Activities

($31.7 m)($66.1 m)

Short-term Borrowings

($5.8 m)($5.8 m)

Cash From Financing Activities

$125.5 m$53.1 m

Interest Paid

$89 k$89 k

Inotek Pharmaceuticals Market Value History

Inotek Pharmaceuticals Company Life

You may also be interested in